Background: Non-small cell lung cancer (NSCLC) in young adults is a rare but devastating illness with significant socioeconomic implications, and studies of this patient subgroup are limited. Aim: This study employed the National Lung Cancer Audit to compare the clinical features and survival of young adults with NSCLC with the older age groups. Design: A retrospective cohort review using a validated national audit dataset. Methods: Data were analysed for the period between 1 January 2004 and 31 December 2011. Young adults were defined as between 18 and 39 years, and all others were divided into decade age groups, up to the 80 years and above group. We performed logistic and Cox regression analyses to assess clinical outcomes. Results: Of a total of 1 46 422 patients, 651 (0.5%) were young adults, of whom a higher proportion had adenocarcinoma (48%) than in any other age group. Stage distribution of NSCLC was similar across the age groups and 71% of young patients had stage IIIb/IV. Performance status (PS) was 0-1 for 85%. Young adults were more likely to have surgery and chemotherapy compared with the older age groups and had better overall and post-operative survival. The proportion with adenocarcinoma, better PS and that receiving surgery or chemotherapy diminished progressively with advancing decade age groups. Conclusion: In our cohort of young adults with NSCLC, the majority had good PS despite the same late-stage disease as older patients. They were more likely to have treatment and survive longer than older patients.
Introduction
The median age of presentation of lung cancer in England is 72 years and only 1-2% of people are younger than 40 years of age at diagnosis. 1 There has been one large study of 2775 younger patients based on the surveillance epidemiology and end results (SEER) programme in USA, but the clinical data were relatively limited. 2 The majority of studies have been small scale (range 22-115), single centre, retrospective case note reviews 1, [3] [4] [5] [6] [7] [8] ; although one study from Shanghai did compare clinical features and outcomes for 652 adults drawn from 175 hospitals in the surrounding area. 9 Cancer Registries may be more representative of the whole population, but they often lack clinical details such as performance status (PS) and co-morbid illness. 5, 10, 11 Some studies have reported a poorer prognosis in young adults, 4, 7, 12 without a clear explanation, whilst others have reported an equivalent prognosis to older patients following surgery. 6, 13, 14 This study aimed to employ the previously validated English National Lung Cancer Audit dataset (NLCA) 15 to describe the sociodemographic and clinical features, as well as treatment and survival data for patients aged 18-39 years, and to compare these features with those of older patients.
Methods
Data from NLCA for all adult patients with primary lung cancer first presenting to their National Health Service (NHS) hospital between 1 January 2004 and 31 December 2011 were used. No formal ethical approval was required as all data are anonymous.
Patients aged 18 to 39 years (inclusive) at diagnosis were grouped together and the remainder of the cohort divided into 10-year age groups at diagnosis, up to those aged 80 years and older. We excluded those patients with carcinoid tumours, mesothelioma and small cell lung cancer from all analyses. We compared the young adult group with the older groups for the following key clinical features: sex, histological subtype, World Health Organisation PS (as a marker of physical fitness) and stage at presentation (Union for International Cancer Control versions 6 and 7). Patients with systematized nomenclature of medicine (SNOMED) codes representing unknown type of lung cancer and those missing codes were grouped with non-small cell lung cancer (NSCLC). 16 The histological subtype of NSCLC was based on SNOMED codes where recorded and followed the categories defined in the NLCA data manual.
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The NLCA was linked to hospital episode statistics (HES) allowing the calculation of the Charlson co-morbidity Index for every patient. 18 This creates a weighted score of co-morbid disease that has been validated in cohorts of men and women with both malignant and non-malignant diseases. We derived the Townsend quintile for socioeconomic deprivation for each patient, from the lower super output area based on the residential postcode of each patient. Quintile 1 is most affluent, and quintile 5 is the least affluent. We performed multivariate logistic regression to assess the likelihood of receiving each treatment modality across the different age groups. Patients in their 70s were used as the reference group. The definitions of having had radiotherapy and chemotherapy were based on the recording of these treatments in the patients' NLCA record. To determine surgical treatment, we identified patients in HES with an Office of Population Censuses and Surveys classification of Interventions (OPCS-4) code consistent with potentially curative surgery, as described by Powell et al. 19 We assessed survival from the date of diagnosis as recorded in the NLCA database. In the absence of a diagnosis date, we used the date of their first hospital appointment to derive a surrogate date. This was done by calculating the median number of days for the whole cohort between each patient's date of first appointment and their date of diagnosis and interpolating a surrogate date of diagnosis. Only 4981 patients (3%) did not have an existing diagnosis date. An end date was generated using either the date of death (obtained from the Personal Demographics Service), or the date the dataset was downloaded, which was 31 December 2011. Cox regression analysis was used to calculate unadjusted hazard ratios for mortality in each age group referenced to patients in the 70-to 79--year group, and a multivariate model constructed to adjust for the key clinical features.
Results
There were a total of 1 76 638 patients seen at English NHS Trusts between 1 January 2004 and 31 December 2011 (first appointment). We excluded 1500 patients (0.8%) for whom the end date was prior to the start date and 14 patients who were younger than 18 years of age, leaving a total of 1 75 124 patients. The 18-to 39-year group comprised 810 patients, 0.5% of the total. Within this group of young adults, 11 (1%) had proven mesothelioma, 47 (6%) had small cell lung cancer and 101 (12%) had carcinoid tumours. These tumour groups were then excluded, leaving 651 young adults and an overall cohort of 1 46 422 patients with NSCLC. Table 1 illustrates the key clinical features by age group. The sex ratio in the young adult group was 1.3 male to female, similar to that for the whole cohort (1.4-1). The proportion of individuals with adenocarcinoma reduced with increasing age: 30%, in the 18-39 group and 19% in the 70-79 group (v 2 test P < 0.001). The proportion of individuals with squamous cell carcinoma increased with age: 8% in the 18-to 39-year-old group compared with 22% in the 70-79 group (v 2 test P < 0.001).
Key clinical features
The PS at diagnosis was missing in 37% of the young group, but was recorded as 0 or 1 in 85% of the remainder. Only 9 patients were recorded with a PS of 4 (2%), compared with 2381 (6%) of the patients aged 70-79 years with PS recorded. The proportion of patients with a Charlson Index of zero (no recorded co-morbid illness in HES), declined from 55% in the young adult group to 31% in patients aged 70-79 years. Table 2 illustrates the co-morbid diseases recorded in HES at the point of diagnosis in our young adults; and although more than half had no co-morbid disease recorded, and 200 (31%) had metastatic disease from their lung cancer; a further 47 (7%) patients had another solid organ tumour prior to their lung cancer diagnosis. There were a handful of adults with conditions ranging from peptic ulcer disease, to stroke and diabetes. Data on socioeconomic status were missing in 11-13% of patients across all age groups (Table 1 ). In those with data, a third of young adult patients were from the least affluent socioeconomic quintile, whilst only 11% were from the most affluent. In contrast, 24% of patients aged 70-79 years at diagnosis were from the least affluent, and 16% were from the most affluent quintile (v 2 test P < 0.001).
Our results showed 260 (40%) young adult patients did not have stage at diagnosis recorded in the NLCA dataset. Of the remaining 391 patients, 279 (71%) had stage 3b or stage 4 disease, and only 57 (15%) had stage I or II disease (Table 1) .
Treatment
Surgical resection was performed in 134 (21%) of the young adult patients, of whom 63 also received chemotherapy, 11 radiotherapy and 10 trimodality treatment. Chemotherapy alone was given to 232 (36%) young patients with NSCLC, radiotherapy alone to 36 (6%) and combination chemo-radiotherapy to 122 (17%). A total of 147 patients (23%) in the young adult cohort had no treatment information recorded, compared with 22 600 (44%) of the 70-to 79-year-old group. Table 3 shows the relationship between the age of a patient and the treatment they received. Young adults with NSCLC were more likely to have both surgery and chemotherapy than those aged 70-79 years (adjusted OR 1.66, 95% CI 1.32, 2.09; and 3.96, 95% CI 3.33, 4.70, respectively). There was no clear variation in the use of radiotherapy across the age groups.
Survival
Cox regression analyses revealed young adults with NSCLC had a lower overall mortality than patients from all other age groups (Table 4 ). Young adults who had surgery were half as likely to die compared with those aged 70-79 years treated surgically (adjusted HR 0.49, CI 0.36, 0.67). When patients with presumed NSCLC were excluded, the survival benefit for those with proven NSCLC who had surgery was reduced, but no worse than those aged 70-79 years.
Discussion

Principal findings
We have found differences in clinical features between young adults with NSCLC and older patients with some progressive trends with increasing age. We found a higher proportion of young adults had adenocarcinoma, and significantly fewer had squamous cell carcinoma. A higher proportion of patients had late stage disease at diagnosis but the PS and level of co-morbidity was more favourable. Young adults with NSCLC were 66% more likely to have surgery compared with older patients and almost four times as likely to have chemotherapy. The likelihood of receiving radiotherapy was approximately equal amongst all patients, which may reflect the use of radiotherapy in palliative as well as potentially curative treatment regimens Male  364  56  1919  52  8 630  56  22 749  58  30 470  59  19 669  55  Female  287  44  1795  48  6 914  44  16 272  42  21 079  41  16 
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as data recorded in the NLCA cannot reliably differentiate treatment intent. Mortality was less in the young adult group overall, and this survival advantage was maintained in those who had surgery, even if no histology was recorded pre-surgical resection.
Our data confirm previously published evidence that adenocarcinoma is more common in this young adult group and squamous cell carcinoma less common. 1, 2, 5, 8, 11, 12, 20, 21 This may reflect both a lower smoking prevalence 22 and duration of exposure to tobacco smoke in this age group, thereby reducing the proportion of tumour types most closely linked with smoking. 23 There is evidence that the incidence of adenocarcinoma is rising overall, 24, 25 with an increase in younger women (15-49 years). 10 
Strengths and limitations
The strength of our study lies in the large cohort of patients aged between 18 and 39 years, drawn from a validated, contemporary national cohort of unselected patients with lung cancer. 15 The NLCA includes robust clinical and demographic data (enhanced by linkage with HES), which can be used to assess potential inequalities in patient care and survival based on age.
A limitation of the NLCA is that a number of data fields have missing data, although the proportion of missing data fields was similar across the age groups studied. The proportion of missing data has decreased progressively over time and the quality of the dataset is improving each year. 26, 27 Despite this limitation, our cohort of 651 young adult patients with NSCLC is the third largest described in the literature and has more comprehensive clinical data.
Comparison with other studies
There is very little published literature on lung cancer in a young adult population, and these studies are usually small, retrospective case series in one medical institution. 1, [3] [4] [5] [6] [7] Unlike the paper from Liu et al. 28 our data are not restricted to one histological subtype, nor to one treatment modality, or one medical institution. Retrospective studies have confirmed the low rate of early stage disease in the young adult group demonstrated here. 4, 7, 8, 28 Lara et al. 29 reported 80% of their cohort, adults <50 years of age with NSCLC from the California Registry, had stage 3 or 4 disease. Late stage at diagnosis could be attributed to young adults taking longer to present and being more likely to be symptomatic at diagnosis. 30, 31 Unfortunately data regarding time from symptoms to presentation and diagnosis are not available in the NLCA. The proportion of patients without evidence of treatment appears high (23%), but it may reflect inconsistent data entry into the NLCA dataset, in addition to late stage at presentation. Green et al. 7 described a population with a similar high proportion of late stage disease, and the rate of 'no treatment' was 42%. We found evidence that mortality was better in the young adult group overall, in contrast to some published data, 4, 7, 12, 30 but in keeping with others. Five-year overall survival was better in the young adult cohort in SEER, which is in keeping with our results of overall mortality. In contrast to our linked dataset from the NLCA and HES, the SEER programme does not record information on PS, comorbidity and treatment. Surgical case series with between 20 and 110 young adult patients 3, 6, 13, 14 have shown no adverse survival in the young adults, which is in keeping with our findings (n ¼ 134 with resected NSCLC). Duan et al. 32 performed a retrospective case note review of 68 patients with primary lung cancer aged <30 years, and reported a 5-year survival of 31%, and in those who had radical surgery it was 36%. We also found that young adults with NSCLC were slightly more likely to come from less affluent areas, which may be important, given Lara et al. 29 described more affluent status was a marker of good prognosis. Individuals from deprived backgrounds are often hard to reach in terms of engaging with 
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health services and will be more likely to present with latestage disease.
Conclusion
Our research has shown that young adult patients with NSCLC in England are more likely to have adenocarcinoma. They are less likely to have early-stage disease at presentation, but have less co-morbidities and a better PS at diagnosis than older patients. We have shown these young adults are more likely to have surgery and chemotherapy than older patients, and they are less likely to die. There was a progressive trend in the differences according to age rather than the young adult patients representing a unique or idiosyncratic group.
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